Objective: To study the effect of danhong injection combined with nadroparin calcium on serum CyS-C, CRP, IL-6, vWF, ET and VEGF in patients with acute coronary syndrome. Methods: A total of 80 patients with acute cor...Objective: To study the effect of danhong injection combined with nadroparin calcium on serum CyS-C, CRP, IL-6, vWF, ET and VEGF in patients with acute coronary syndrome. Methods: A total of 80 patients with acute coronary syndrome in our hospital from July 2014 to July 2017 were enrolled in this study. The subjects were divided into the control group (n=40) and the treatment group (n=40) randomly. The control group was treated with xuesaitong injection combined with nadroparin calcium;the treatment group was treated with danhong injection combined with nadroparin calcium. The two groups were treated for 2 weeks. The serum CyS-C, CRP, IL-6, vWF, ET and VEGF levels of the two groups before and after treatment were compared. Results: There were no significantly differences of the serum CyS-C, CRP, IL-6, vWF, ET and VEGF levels of the two groups before treatment. The serum CyS-C, CRP, IL-6, vWF, ET and VEGF levels of the two groups after treatment were significantly lower than before treatment, and that of the treatment group were significantly better than that of the control group. Conclusion: Danhong injection combined with nadroparin calcium can significantly reduce the serum CyS-C, CRP, IL-6, vWF, ET and VEGF levels of patients with acute coronary syndrome, and it was worthy clinical application.展开更多
Background American College of Cardiology/American Heart Association/European Society of Cardiology （ACC/AHA/ESC） guidelines gave fondaparinux a class Ⅰ recommendation for use in patients with non-ST elevation acut...Background American College of Cardiology/American Heart Association/European Society of Cardiology （ACC/AHA/ESC） guidelines gave fondaparinux a class Ⅰ recommendation for use in patients with non-ST elevation acute coronary syndromes （NSTE-ACS） undergoing invasive or conservative strategy. Nadroparin is one of the common anticoagulants used in NSTE-ACS in China. Accordingly, this study compared the safety and efficacy between fondaparinux and nadroparin in patients with NSTE-ACS.Methods In this prospective, randomized, open-label, and single center study, a total of 300 patients with NSTE-ACS were randomized to receive either fondaparinux （group F, n=150, 2.5 mg/d） or nadroparin （group N, n=150, 0.1 ml/10 kgq12 h） for a mean of 4 days. The primary safety endpoint was the incidence of major or minor bleeding at 9 days that was not related to coronary artery bypass grafting （CABG）. The primary efficacy endpoints included death, myocardial infarction, or recurrent ischemia at 9 days. All patients underwent a 180-day follow-up.Results Baseline characteristics were well matched between the two groups. There was a non-significant 28% relative risk reduction in the primary safety endpoint in group F compared with group N （4.7% vs. 6.7%, HR 0.72, 95% CI0.42-1.65, P=0.38）. The primary efficacy endpoint was 8.0% in group F and 10.0% in group N （HR, 0.82, 95% CI0.54-1.71, P=0.49）. The composite of the safety and efficacy endpoints at 9 days （10.0% vs. 16.0%, HR 0.61, 95% CI0.31-1.10,P=0.10）, 30 days （14.0% vs. 17.9%, HR 0.72, 95% C/0.47-1.16, P=0.21）, or 180 days （18.7% vs. 27.3%, HR0.65, 95% CI0.38-1.11, P=0.11） showed a non-significant trend toward a lower value in group F.Conclusion Fondaparinux resulted in a nonsignificant risk reduction in patients with NSTE-ACS in both bleeding and ischaemic events during short- and long-term follow-up compared with nadroparin.展开更多
目的比较磺达肝癸钠、那屈肝素钙对骨科大手术后静脉血栓、血栓弹力图(thromboelastography,TEG)参数、预后的影响。方法选取2022年1月—2023年9月收治的120例拟行骨科大手术患者作为研究对象,随机分为对照组和观察组,各60例。对照组采...目的比较磺达肝癸钠、那屈肝素钙对骨科大手术后静脉血栓、血栓弹力图(thromboelastography,TEG)参数、预后的影响。方法选取2022年1月—2023年9月收治的120例拟行骨科大手术患者作为研究对象,随机分为对照组和观察组,各60例。对照组采取那屈肝素钙治疗,观察组采取磺达肝癸钠治疗,连续治疗2周。比较2组静脉血栓发生率、不良反应及治疗前后下肢静脉血流速度、TEG参数、预后[简明健康状况量表(medical outcomes study 36-item short-form health survey,SF-36)、Barthel指数(Barthel index,BI)]。结果观察组的血栓事件总发生率低于对照组(0 vs.10.00%,P<0.05);2组治疗2周后的股静脉、腘静脉血流速度比较差异无统计学意义(P>0.05);观察组治疗2周后的MA值、α角分别为(54.42±4.31)mm、(57.62°±5.53°),低于对照组的(59.59±4.66)mm、(60.81°±6.17°),R值、K值分别为(4.82±1.11)min、(2.40±0.61)min,高于对照组的(4.11±0.89)min、(2.08±0.57)min(P<0.05);2组不良反应发生率比较差异无统计学意义(8.33%vs.3.33%,P>0.05);治疗后3个月2组的SF-36、BI评分高于治疗前(P<0.05),但2组比较差异无统计学意义(P>0.05)。结论骨科大手术后使用磺达肝癸钠治疗更有助于预防静脉血栓发生,可改善血液高凝状态,其与那屈肝素钙相比具有一定优势,但两者在生活质量、日常生活能力及安全性方面的作用相似。展开更多
基金Project of Jiangsu Natural Science Foundation of China(BK2012561).
文摘Objective: To study the effect of danhong injection combined with nadroparin calcium on serum CyS-C, CRP, IL-6, vWF, ET and VEGF in patients with acute coronary syndrome. Methods: A total of 80 patients with acute coronary syndrome in our hospital from July 2014 to July 2017 were enrolled in this study. The subjects were divided into the control group (n=40) and the treatment group (n=40) randomly. The control group was treated with xuesaitong injection combined with nadroparin calcium;the treatment group was treated with danhong injection combined with nadroparin calcium. The two groups were treated for 2 weeks. The serum CyS-C, CRP, IL-6, vWF, ET and VEGF levels of the two groups before and after treatment were compared. Results: There were no significantly differences of the serum CyS-C, CRP, IL-6, vWF, ET and VEGF levels of the two groups before treatment. The serum CyS-C, CRP, IL-6, vWF, ET and VEGF levels of the two groups after treatment were significantly lower than before treatment, and that of the treatment group were significantly better than that of the control group. Conclusion: Danhong injection combined with nadroparin calcium can significantly reduce the serum CyS-C, CRP, IL-6, vWF, ET and VEGF levels of patients with acute coronary syndrome, and it was worthy clinical application.
文摘Background American College of Cardiology/American Heart Association/European Society of Cardiology （ACC/AHA/ESC） guidelines gave fondaparinux a class Ⅰ recommendation for use in patients with non-ST elevation acute coronary syndromes （NSTE-ACS） undergoing invasive or conservative strategy. Nadroparin is one of the common anticoagulants used in NSTE-ACS in China. Accordingly, this study compared the safety and efficacy between fondaparinux and nadroparin in patients with NSTE-ACS.Methods In this prospective, randomized, open-label, and single center study, a total of 300 patients with NSTE-ACS were randomized to receive either fondaparinux （group F, n=150, 2.5 mg/d） or nadroparin （group N, n=150, 0.1 ml/10 kgq12 h） for a mean of 4 days. The primary safety endpoint was the incidence of major or minor bleeding at 9 days that was not related to coronary artery bypass grafting （CABG）. The primary efficacy endpoints included death, myocardial infarction, or recurrent ischemia at 9 days. All patients underwent a 180-day follow-up.Results Baseline characteristics were well matched between the two groups. There was a non-significant 28% relative risk reduction in the primary safety endpoint in group F compared with group N （4.7% vs. 6.7%, HR 0.72, 95% CI0.42-1.65, P=0.38）. The primary efficacy endpoint was 8.0% in group F and 10.0% in group N （HR, 0.82, 95% CI0.54-1.71, P=0.49）. The composite of the safety and efficacy endpoints at 9 days （10.0% vs. 16.0%, HR 0.61, 95% CI0.31-1.10,P=0.10）, 30 days （14.0% vs. 17.9%, HR 0.72, 95% C/0.47-1.16, P=0.21）, or 180 days （18.7% vs. 27.3%, HR0.65, 95% CI0.38-1.11, P=0.11） showed a non-significant trend toward a lower value in group F.Conclusion Fondaparinux resulted in a nonsignificant risk reduction in patients with NSTE-ACS in both bleeding and ischaemic events during short- and long-term follow-up compared with nadroparin.
文摘目的比较磺达肝癸钠、那屈肝素钙对骨科大手术后静脉血栓、血栓弹力图(thromboelastography,TEG)参数、预后的影响。方法选取2022年1月—2023年9月收治的120例拟行骨科大手术患者作为研究对象,随机分为对照组和观察组,各60例。对照组采取那屈肝素钙治疗,观察组采取磺达肝癸钠治疗,连续治疗2周。比较2组静脉血栓发生率、不良反应及治疗前后下肢静脉血流速度、TEG参数、预后[简明健康状况量表(medical outcomes study 36-item short-form health survey,SF-36)、Barthel指数(Barthel index,BI)]。结果观察组的血栓事件总发生率低于对照组(0 vs.10.00%,P<0.05);2组治疗2周后的股静脉、腘静脉血流速度比较差异无统计学意义(P>0.05);观察组治疗2周后的MA值、α角分别为(54.42±4.31)mm、(57.62°±5.53°),低于对照组的(59.59±4.66)mm、(60.81°±6.17°),R值、K值分别为(4.82±1.11)min、(2.40±0.61)min,高于对照组的(4.11±0.89)min、(2.08±0.57)min(P<0.05);2组不良反应发生率比较差异无统计学意义(8.33%vs.3.33%,P>0.05);治疗后3个月2组的SF-36、BI评分高于治疗前(P<0.05),但2组比较差异无统计学意义(P>0.05)。结论骨科大手术后使用磺达肝癸钠治疗更有助于预防静脉血栓发生,可改善血液高凝状态,其与那屈肝素钙相比具有一定优势,但两者在生活质量、日常生活能力及安全性方面的作用相似。
